Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: Interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2059-2066

  Vuylsteke, P ^a   Huizing, M ^b   Petrakova, K ^c   Roylance, R ^d   Laing, R ^e   Chan, S ^f   Abell, F ^g   Gendreau, S ^h   Rooney, I ^h   Apt, D ^h   Zhou, J ^h   Singel, S ^h   Fehrenbacher, L ⁱ  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^h GENENTECH INC   (United States)

ⁱ KAISER PERMANENTE   (United States)

Author keywords

HER2 negative; Hormone receptor positive; Metastatic breast cancer; PI3K; Pictilisib; PIK3CA

Indexed keywords

PACLITAXEL; PICTILISIB; PLACEBO; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; INDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BC CELL LINE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ERYTHEMA; FEMALE; GASTROENTERITIS; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERGLYCEMIA; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PI3K/AKT SIGNALING; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN ALLERGY; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDAZOLES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECEPTOR, ERBB-2; SULFONAMIDES;

EID: 85016766194     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw320     Document Type: Article

References (17)

1. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23: 489-502
2. Gradishar WJ, Anderson BO, Balassanian R et al. Breast cancer version 2.2015. J Natl Compr Canc Netw 2015; 13: 448-475
3. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29: 4452-4461
4. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw 2013; 11: 670-678
5. Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev 2016; 45: 87-96
6. Arthur LM, Turnbull AK, Renshaw L et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrinetreated breast cancer. Breast Cancer Res Treat 2014; 147: 211-219
7. Folkes AJ, Ahmadi K, Alderton WK et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51: 5522-5532
8. O'Brien C, Wallin JJ, Sampath D et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16: 3670-3683
9. Wallin JJ, Guan J, Prior WW et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res 2012; 18: 3901-3911
10. Sarker D, Ang JE, Baird R et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 77-86
11. Schmid P, Pinder SE, Wheatley D et al. Phase II randomized preoperative windowof-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2016; 34: 1987-1994
12. Schöffski P, Cresta S, Mayer IA et al. Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer. Cancer Res 2015; 75: abstr P5-19-10 (and associated poster presentation)
13. Von Hoff D, LoRusso P, Demetri GD et al. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol 2011; 29(Suppl): abstr 3052
14. Krop IE, Mayer IA, Ganju V et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17; 811-821
15. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074
16. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014; 6: 154-166
17. Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther 2014; 13: 2477-2488